Maturity of the Lamb Immune System by Gailor, Mabel
  
 
 
Maturity of the Lamb Immune System  
 
 
 
 
 
 
 
 
 
 
Honors Thesis 
 
Presented to the College of Agriculture and Life Sciences,  
Department of Animal Sciences 
of Cornell University 
in Partial Fulfillment of the Requirements for the 
Research Honors Program 
 
By 
Mabel Elizabeth Gailor 
May 2007 
 
Dr.Jerrie Gavalchin 
Dr. Michael Thonney 
 
 
 
ABSTRACT 
Vaccines targeting specific threats to lamb health could be immensely 
instrumental in curbing high levels of lamb mortality in the U.S. lamb industry. However, 
the age at which vaccine administration would be most beneficial is currently unspecified 
due to limited knowledge of when lambs become immunocompetent. This study’s main 
objective was to determine the effect of age on the immunological competency of sheep 
in order to determine the optimal schedule for vaccinating lambs. An experiment was 
designed to examine the ability of lambs of varying ages to mount an antigen-specific 
immune response against Keyhole Limpet Hemocyanin (KLH) after vaccination with 
KLH in 10% aluminum hydroxide as the adjuvant. Groups of five lambs were vaccinated 
subcutaneously with one of three treatments (vaccine, control, adjuvant only) three times 
at two week intervals over a total of six weeks. The age at administration of the treatment 
was also variable (n=5); the lambs were either 0, 5, or 40 weeks of age at the start of their 
respective six week vaccine trial. Three blood samples were taken immediately prior to 
the second and third treatment and two weeks after the third. Lymphocyte proliferation, 
and production of total immunoglobulin (Ig), and KLH-specific Ig were measured. An 
increase in lymphocyte production in vaccinated animals in response to vaccines was 
seen as early as 4 weeks of age, after two vaccines. The production of anti-KLH Ab in 
vaccinated lambs began after the first vaccination and had a fold response four times as 
high as control and adjuvant-only animals when sampled two weeks after the first 
vaccination.  
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Introduction 
Lamb health is a major area of concern in the lamb meat industry as lamb 
mortality can be a limiting factor in the profitability of sheep operations. Mortality rates 
are estimated to be between 15 and 51% with rates as high as 35% considered acceptable 
among large sheep operations (Daniels et al., 2000). When experiencing acute disease 
outbreaks, losses approaching 100% have been observed (Shelton and Willingham, 
2002). To help avoid and prevent such economically detrimental events, it is critical to 
understand the development of the lamb’s immune system in the first few weeks of life in 
order to determine the appropriate age at which vaccines can be administered to generate 
protective immune responses. 
 Current immunization practices focus on immunizing the pregnant ewe before 
parturition to confer the best possible repertoire of antibodies (Ab) and passive immunity 
to the lamb via colostrum (reviewed in Butler, 1999). Colostrum contains antibodies to 
diseases prevalent to in a specific flock, and to diseases that an ewe has been vaccinated 
against, and helps prevent disease outbreak in lambs. Although this passive immunity 
works well to protect most lambs against common infectious agents for the first ten to 
twelve weeks of life, it is dependent both on the strength of the ewe’s immune system 
and the quantity of colostrum received by the lamb. Thus, there can be a high degree of 
variability in the quality of passive immunity acquired by lambs.  Determination when 
immune competence develops during the crucial first weeks of life will identify the 
earliest time point for effective vaccination to help prevent some of the infectious 
diseases responsible for postnatal lamb losses. Further, the ability to launch an antigen-
specific active immune response would provide the lamb with the opportunity to protect 
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itself against virtually any possible antigenic threat, independent of passive immunity 
from the ewe..  
 The objective of this study was to examine the age at which immunological 
competency is achieved in postnatal Finnsheep x Dorset lambs. To investigate this, lambs 
were vaccinated with KLH in alum or alum alone at  0, 5 weeks, or 40 weeks of age and 
the KLH-specific cellular and humoral responses measured in terms of leukocyte 
proliferation, total IgG, and KLH specific IgG production.  
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Review of the Literature 
 
 Much of the previous research on the immune system of the lamb has 
focused on the importance of passive immunity from the ewe in protection from 
infections. Passive immunity is conferred from ewe to lamb through colostrum in the first 
24h after birth. The level of immunity provided by colostrum is related to the level of 
systemic immunity of the ewe (G. Chappuis et al., 1998). Thus, previous research in lamb 
immunity has focused on strategies to provide effective passive immunity towards 
commonly encountered pathogens in sheep flocks. A definitive study examining the 
immunocompetency of lambs in response to vaccination at varying ages is needed to 
determine when the immune system of the lamb is able to produce a protective immune 
response including antibodies. 
Vaccination studies in the 1960’s testing intramuscular immunization of newborn 
lambs found that the vaccines were ineffective, presumably due to the blocking effects of 
maternally-derived passive immunity (Mutwiri et al., 2000).  In a later study, De la Rosa 
et al (1997) found that vaccinating pregnant ewes imparted protective immunity in lambs 
against enterotoxemia (a common pathogen) for 12 weeks, and the vaccination of the 
lambs themselves provided no added immunological protection. Again, it was concluded 
that vaccine-induced antibody production in the neonatal lambs was suppressed by the 
presence of maternally-derived antibodies, as the immune response in vaccinated lambs 
was diminished response whether or not their dams had been vaccinated.   
In contrast to De la Rosa’s work, Fahey and Morris in 1978 found that fetal lambs 
were, in fact, capable of launching antibody responses of varying characteristics in terms 
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of Ig type and magnitude in utero, with the amount of antibody produced and persistence 
of the response increasing as the lamb aged. Also in support, several studies have shown 
that early in life ruminants are capable of responding to antigenic threats (Mutwiri et al., 
2000); suggesting that they should be capable of generating immune responses to 
antigens.  
There is a period of time when neonates contain too much maternal antibody in 
their system, preventing them from responding to a vaccine but not sufficient to protect 
against states of disease. Ideally, vaccines should be administered to an animal at the age 
at which it first becomes susceptible to infection, prior to the decline of passive immunity 
(G.Chappuis et al., 1998). Previous studies suggest that a major obstacle to successful 
vaccination of young lambs is the presence of blocking levels of maternally- derived 
antibodies. This blocking effect of maternal immunoglobulin may be overcome if the 
antigenicity of a vaccine is improved over that of traditional vaccines, or when a naïve (to 
the lamb’s system) vector is used to present the antigen (G.Chappuis et al., 1998). 
Strategies using multiple boosters of vaccine have also been found to improve 
immune responses. In a 1997 study by Bar-Joseph et al., 3 month old Romanov x Awassi 
cross lambs that received a primary immunization containing a recombinant virus coat 
protein and then were boosted three weeks later with a partially purified native antigen 
produced more effective immune responses to antigen. It was found that giving boosters 
(secondary vaccines) to lambs three weeks after the initial vaccine produced higher titers 
in sera of Ig compared to lambs that had received single doses of antigen.  Lambs that 
were not primed with a first dose of antigen, but did receive the second booster dose 
failed to produce a substantial response 12-15 days later.  
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Like all mammals, the lamb’s immune system matures as it ages. Thus, the 
response to an antigen will vary based on the age of the animal at the time of vaccine 
administration. J.M. Corpa et al. in 2000 noted differences in the quality of the immune 
response induced in lambs aged 15 days and 5 months. The older lambs consistently 
developed a higher and more persistent antibody response to antigen, possibly due to 
incomplete immune system maturation in the 15 day old lambs. Mutwiri et al. (2000) also 
found that newborn lambs exhibited systemic immune responses with lower levels of Ig 
than 5-6 week old lambs.  
To account for variation in the maturity of the immune system several studies 
look at immune profiles as they developed over a period of time. Premier et al. in 2003 
designed a study to examine antibody isotype profiles in sheep sera and circulating cells 
in which sheep were immunized three times at two week intervals with Keyhole Limpet 
Hemocyanin (KLH), an immunostimulant and carrier protein derived from the mollusk 
Megathura crenulata and augments both the cellular and humoral components of immune 
responses (Linn et al., 2000). Premier’s study found that the route of vaccine 
administration affects the immunological response and that antibody secreting cells can 
be successfully used to assay humoral responses in ruminants.  
Using a similar vaccination schedule, Sedgmen et al. in 2005 investigated 
antibody production in 1-2 year old sheep immunized three times over a seven week 
period, also with KLH. This schedule allowed the researchers to study antibody response 
over a period of time to obtain an immune response profile.  
Most studies to date have examined antibody production after vaccination.  
Another approach would be to measure lymphocyte activation. Concanavalin A (con A) 
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is a commonly used mitogen that is used to measure activation of unprimed T cells in 
proliferation assays (Kruisbeek et al., 2007). Another mitogen, pokeweed mitogen 
(PWM) works through T cell dependent activation of B cells (James et al., 2007). Since 
the activation of lymphocytes occurs before Ig production, examination of proliferative 
responses of lymphocytes to various mitogens and antigens after vaccination may provide 
additional information regarding immune competency.  
 
Materials and Methods 
Animals 
 The experiment was a 3 x 3 experiment, with 3 ages at initial vaccination (0 wk, 5 
wk, and 10 mo) and 3 vaccination treatments: 1) control (no injection); 2) adjuvant 
(adjuvant injection); 3) vaccine (adjuvant plus antigen injection). Five sheep were 
randomly assigned to each of the 6 treatments (Table 1). Both ewe and ram lambs were 
used, but no attempt was made to stratify genders across treatments. The lambs used as 0 
week and 5 week samples were born between October 24 and October 29, 2006. For 
sampling and processing ease, the week 0 and week 5 age groups were split into separate 
0A, 0B, 5A, 5B components. Fifteen 10 month old lambs were also randomly assigned to 
one of the three vaccine treatment groups (Table I). The sampling dates are outlined in 
Appendix A. During the study all animals were housed and maintained indoors at 
Cornell’s TNR sheep facility.  
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Table I: Lamb Assignment to Vaccine Treatment 
Error! Not a valid link. 
 
Vaccinations and Blood Collection 
 Sheep in the vaccine and adjuvant treatment groups were immunized 
subcutaneously in the neck three times at two week intervals with 500μL volumes 
containing 250μg of KLH (Sigma, MO, USA) with 10% alum hydroxide gel as adjuvant 
or adjuvant alone.  
 Blood samples (25mL) were collected using Vacutainer ® tubes; 2 (5ml) red-
topped tubes for sera collection and two 10 ml heparin-treated (green-topped) tubes for 
isolation of lymphocytes. The first two blood samples were obtained immediately prior to 
the second and third immunizations, respectively and the last, 14 days after the third 
immunization. . Sera was collected from the clotted blood samples by centrifuging at 
1800 xg for 10 minutes and stored at -20°c until analysis. The heparin-treated tubes were 
processed in the same day to isolate lymphocytes to be used in the proliferation and Ig 
assays.  
 
Preparation of Lymphocytes 
 Lymphocyte proliferation in response to KLH was measured using the CellTiter 
96 Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI). Lymphocytes 
were isolated from the non-heparinized blood samples by density gradient centrifugation.  
First the blood was diluted 1:1 with 10ml RPMI 1640 medium,   layered over 10ml of 
Ficoll- Histopaque and then centrifuging at 2300 xg for 20 minutes. The interphase 
containing lymphocytes was removed into 10ml RPMI media. The cells were then 
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pelleted by spinning at 1200 xg for 10 minutes.  Red blood cells in the samples were then 
lysed by the addition of 5ml tris ammonium chloride (TAC), pH 7.0 for 5 minutes at 
room temperature. Five ml RPMI media was added and the cells were centrifuged at 
1200 xg for 10 minutes. The supernatant was removed and then 0.5-1.0ml of a media 
consisting of RPMI 1640 supplemented with 10% fetal calf serum, 2mM glutamine, 
100µg/ml penicillin and 100µg/ml streptomycin was added (RPMI+). The cells were 
counted using trypan blue exclusion.  
 
Proliferation Assay 
 Cells at a concentration of 1 x 10e-7 cells/ml were dispensed in 50µl volumes into 
the wells of a 96-well plate with 50µl of KLH, Concanavalin A (Con A), or poke weed 
mitogen (PWM). All mitogens were prepared to a concentration of 50μg/ml. Control 
cultures received media alone. The cell cultures were incubated for 4 days at 37°C under 
5% CO2.  
 After incubation, the CellTiter 96 Non-Radioactive Cell Proliferation assay was 
according to the manufacturer’s instructions to measure proliferation. Fifteen µl of MTT 
dye solution was added to each well and the plate was incubated for four hours. The 
reaction was stopped by the addition of 50µl of the solubilization/ stop solution. The 
amount of proliferation was determined by quantitation of the absorbance levels at 
570nm using a Genios Multi-Detection Microplate Reader (Tecan) and Magellan 
software.   
 
Immunoglobulin Assay 
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 One million cells (100 μL volume) were dispensed in duplicate to the wells of a 
24-well plate. For the blank well, 400µl/well of RPMI+ was added. KLH (50µl) at 50 
μg/ml was added to the second well in a total volume of 500µl in each well. The cells 
were incubated for 7 days and then frozen at -70°C until the Ig content of the supernatant 
was assayed.  
 Enzyme-linked immunosorbent assay (ELISA) was used to measure levels of IgG 
present in the cell culture supernatant. Immulon 1B plates were coated with mouse anti-
bovine/ovine IgG (Serotec) at a 1:500 dilution of carbonate buffer and stored overnight at 
4°C. The plates were then washed twice with 200µl/well PBS-1% Tween and twice with 
PBS. Then non-specific binding was blocked by the addition of 50µl/well 1% BSA for 1 
hour at room temperature. The plates were then washed and 50µl supernatant diluted 1:1 
with PBS-0.1% Tween was added to the plate. The plates were covered with parafilm, 
and incubated overnight at 4°C.  
 The following day, the plates were washed again and 50µl/well anti-bovine IgG, 
A, M conjugated to alkaline phosphatase (Sigma) was added at a dilution of 1:2000 in 
PBS-0.1% Tween. The plates were covered with parafilm, and incubated overnight at 
4°C.  
 The plates were washed and the amount of bound alkaline phosphatase 
determined by the addition of p-nitophenyl phosphate substrate. Color development of 
the substrate was then read at 405nm using Genios Multi-Detection Microplate Reader 
(Tecan) and Magellan software.   
  
KLH- specific Serum Ab Assay 
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 An ELISA similar to the IgG assay was performed to assess the level of anti-KLH 
IgG in the serum samples. Immulon 1B plates were coated with 50µl of KLH (Serotec) in 
a 1:500 dilution of KLH /Carbonate Coating Buffer and incubated overnight at 4°C. The 
plates were then washed twice with 200µl/well PBS-1% Tween and twice with PBS. 
Then non-specific binding was blocked by the addition of 50µl/well 1% BSA for 1 hour 
at room temperature. The plates were then washed and 50µl of serum, diluted 1:10 with 
PBS-0.1% Tween, was added to the plate. The plates were covered with parafilm, and 
incubated overnight at 4°C.  
 The following day, the plates were washed again and coated with 50µl/well anti-
bovine IgG, A, M conjugated to alkaline phosphatase (Sigma) at a dilution of 1:5,000 in 
PBS-0.1% Tween. The plates were covered with parafilm, and incubated overnight at 
4°C.  
 The plates were washed and the amount of bound alkaline phosphatase 
determined by the addition of p-nitophenyl phosphate substrate. Color development of 
the substrate was then read at 405nm using Genios Multi-Detection Microplate Reader 
(Tecan) and Magellan software.   
Statistical Analysis 
 Statistical analysis was performed using Minitab v.15 to run an analysis of 
variance (ANOVA). The data were analyzed within each sampling time (2, 4, 6 wk after 
the initial vaccination). The statistical model included the effect of age at initial 
vaccination (0 wk, 5 wk, 10 mo), the vaccine treatment (control, adjuvant, vaccine), and 
the two-way interaction. 
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Results 
 
Proliferative Responses of Lymphocytes: 
 Lymphocytes from lambs vaccinated with KLH starting at age 0 weeks had a 
higher proliferation index in response to KLH after receiving vaccination booster 
treatments at 4 and 6 weeks of age (Fig. 1a).  As well, the proliferation to the mitogen, 
pokeweed was higher for cells from vaccinated lambs at two weeks of age. At 4 weeks of 
age, the proliferative response of vaccinated animals to PWM was nearly 2-fold higher 
than that of lambs receiving adjuvant alone (Fig. 2a). Likewise, when lymphocytes from 
lambs vaccinated starting at 0 weeks of age were exposed to Con A, the proliferation 
index was nearly two times as high in the vaccine-treated lambs treatment compared to 
the those receiving adjuvant only at age 4 weeks (Fig. 3a).  
 Lymphocytes from lambs vaccinated with KLH starting at age 5 weeks had a 
higher proliferation index in response to KLH at 7 and 9 weeks of age (Fig. 1b). 
However, when lymphocytes from these lambs were exposed to PWM, there was no 
change in the proliferation index regardless of vaccine treatment at all of the three 
sampling times (Fig. 2b). On the other hand, when lymphocytes from these lambs were 
exposed to Con A, the proliferation index of vaccinated animals was higher than that of 
lambs receiving adjuvant alone at age 7 weeks (Fig. 3b). 
 Lambs vaccinated with KLH starting at 10 months of age had an almost 3-fold 
increase in the proliferation index in response to KLH at 46 weeks of age (Fig. 1c). When 
lymphocytes were exposed to PWM, the proliferation index for vaccinated animals was 
higher for all three sampling points, and notably, was over three times greater than that 
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found for lymphocytes from the lambs receiving adjuvant only at the same age (Fig. 2c). 
Likewise, lymphocytes from vaccinated lambs exposed to Con A had a three-fold 
increase in proliferation index compared to lamb that had received  adjuvant only lambs 
at 46 weeks of age(Fig. 3c). 
 For all three mitogens, the greatest proliferative index was observed in samples 
taken at age 46 weeks in the animals that had been vaccinated, beginning at 40 weeks 
(Fig. 1c, 2c, 3c). 
As shown in Table II, ANOVA tests indicate significant (P< 0.05) relationships 
between the age at time of vaccination for the proliferation index of KLH compared to 
blank.  
As well, there was a three-fold increase in the least means squares of lambs 
vaccinated at 10 months old compared to lambs vaccinated at 0 or  5 weeks of age, 
regardless of the mitogen examined (Table III). 
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 Proliferation Response of Lambs Vaccinated at 10 Months
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Figure 1: Proliferative response of lymphocytes from lambs vaccinated at A) 0 weeks of 
age, B) 5 weeks of age, and C) 10 months with KLH in response to KLH. Proliferation 
was assayed using the Promega 96Cell Titer MTT dye assay and absorbency was read at 
570nm. A proliferation index was calculated by comparing KLH proliferation to 
proliferation under control (blank-no antigen or mitogen) conditions. 
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 Proliferation Response to PWM of Lambs Vaccinated at Age 0 Weeks 
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 Proliferation Response to PWM of Lambs Vaccinated at 10 Months
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Figure 2: Proliferative response of lymphocytes from lambs vaccinated at A) 0 weeks of 
age, B) 5 weeks of age, and C) 10 months with KLH in response to PWM. Proliferation 
was assayed using the Promega 96Cell Titer MTT dye assay and absorbency was read at 
570nm. A proliferation index was calculated by comparing KLH proliferation to 
proliferation under control (blank-no antigen or mitogen) conditions. 
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 Proliferation Response to Con A of Lambs Vaccinated at Age 0 Weeks 
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Figure 3: Proliferative response of lymphocytes from lambs vaccinated at A) 0 weeks of 
age, B) 5 weeks of age, and C) 10 months with KLH in response to Con A. Proliferation 
was assayed using the Promega 96Cell Titer MTT dye assay and absorbency was read at 
570nm. A proliferation index was calculated by comparing KLH proliferation to 
proliferation under control (blank-no antigen or mitogen) conditions. 
 
 
 
 
 
 
 
 
 
 
 
Table II: ANOVA for proliferation index of lambs vaccinated with KLH in response to 
exposure to KLH, Con A, or PWM.  
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Analysis of Variance for KLH/BLK, using Adjusted SS for Tests 
Source DF Seq SS Adj SS Adj MS F P 
Vac?      2 0.239 0.325 0.163 0.04 0.962 
Age 2 28.638 27.518 13.759 3.27 0.05* 
Total 4 173.576 143.062 4.208 0.1 0.983 
Error  42 143.062 1.638 0.409   
Vac?*Age  34 1.638     
       
S = 2.05127    R-Sq = 17.58%    R-Sq(adj) = 0.00% 
       
Analysis of Variance for Con A/BLK, using Adjusted SS for Tests 
Source    DF    Seq SS   Adj SS   Adj MS    F    P 
Vac?     2 4.174 4.753 2.376 0.26 0.771 
Age      2 50.156 49.82 24.91 2.74 0.079* 
Vac?*Age  4 2.782 2.782 0.695 0.08 0.989 
Error    34 308.62 308.62 9.077   
Total     42 365.73     
       
S = 3.01283    R-Sq = 15.62%    R-Sq(adj) = 0.00% 
       
Analysis of Variance for PWM/BLK, using Adjusted SS for Tests 
Source DF Seq SS Adj SS Adj MS F P 
Vac?      2 7.819 8.153 4.077 0.54 0.589 
Age     2 33.824 33.112 16.556 2.18 0.128 
Vac?*Age  4 8.285 8.285 2.071 0.27 0.893 
Error    34 257.73 257.73 7.58   
Total    42 307.66     
       
S = 2.75325    R-Sq = 16.23%    R-Sq(adj) = 0.00% 
 
Blood samples were taken two weeks post-vaccination, exposed to mitogen, and 
proliferative response was assayed using MTT dye. 
 
 
 
 
 
 
Table III: Least means squares for proliferation of lymphocytes in response to mitogen 
exposure 
 24
          KLH/BLK Con A/BLK PWM/BLK 
Vac? Mean SEMean Mean SEMean Mean SEMean 
Adjvnt 1.5529 0.5296 2.469 0.7779 2.2276 0.7109 
Control 1.4065 0.5855 1.7341 0.86 1.1287 0.7859 
Vaccine 1.6238 0.5296 1.7999 0.7779 1.7447 0.7109 
Age       
0 0.9646 0.5296 1.1694 0.7779 0.9776 0.7109 
5 0.9667 0.5855 1.3278 0.86 1.2039 0.7859 
10 2.6519 0.5296 3.5058 0.7779 2.9195 0.7109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Production of Immunoglobulin (IgG) 
 25
 Total IgG production was determined using an ELISA assay. Colorimetric results 
were read at 405nm and IgG produced in the presence of KLH was compared to control 
(media alone), and the data reported as fold response IgG over control. Lambs vaccinated 
with KLH starting at age 0 weeks produced more IgG at age 4 and 6 weeks  than lambs 
receiving adjuvant alone (Fig. 4a).    
 Lambs vaccinated at age 5 weeks tended to produce slightly more (~20%) IgG 
than lambs receiving adjuvant only at age 11 weeks (Fig. 4b). 
 Lambs vaccinated with KLH at 10 months old had greater IgG production than 
lambs receiving adjuvant only at age 44 weeks (Fig. 4c). 
 Tables IV, V, and VI show that no significant relationships were seen between 
vaccine treatment, age at time of treatment, nor a cross of the two factors during any 
sample week during the trials.   
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 Total IgG Production in Lambs Vaccinated at 10 Months
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Figure 4: Total IgG production in lambs vaccinated with KLH at A) 0 weeks of age, B) 5 
weeks of age, and C) 10 months of age. IgG production was measured by ELISA and 
expressed as O.D. 405nm; results were expressed as the fold in IgG produced in the 
presence of KLH over IgG production in control (media alone).  
 
 
 
 
 
 
 
 
 
 
Table IV: ANOVA results for IgG Concentrations Assayed Using ELISA for Samples 
Collected on Week 2 of Vaccine Trials 
 28
 
Analysis of Variance for KLH/BLK, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.7037 0.6167 0.3084 0.83 0.446 
VacAge 2 0.4071 0.3923 0.1962 0.53 0.595 
Vac?*VacAge 4 0.3713 0.3713 0.0928 0.25 0.907 
Error 28 10.4004 10.4004 0.3714   
Total 36 11.8826     
S = 0.609462   R-Sq = 12.47%   R-Sq(adj) = 0.00%  
       
Analysis of Variance for KLH-Blank, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.00416 0.00545 0.00272 0.090 0.916 
VacAge 2 0.01804 0.01881 0.0094 0.300 0.74 
Vac?*VacAge 4 0.01142 0.01142 0.00285 0.090 0.984 
Error 28 0.86581 0.86581 0.03092   
Total 36 0.89943     
S = 0.175846   R-Sq = 3.74%   R-Sq(adj) = 0.00%   
 
Table V: ANOVA results for IgG Concentrations Assayed Using ELISA for Samples 
Collected on Week 4 of Vaccine Trials 
 
Analysis of Variance for KLH/BLK, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.8321 0.977 0.4885 2.410 0.107 
VacAge 2 0.4464 0.4214 0.2107 1.040 0.366 
Vac?*VacAge 4 0.1547 0.1547 0.0387 0.190 0.941 
Error 29 5.8665 5.8665 0.2023   
Total 37 7.2997     
S = 0.449769   R-Sq = 19.63%   R-Sq(adj) = 0.00%   
       
Analysis of Variance for KLH-Blank, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.03361 0.04271 0.02136 1.470 0.246 
VacAge 2 0.00624 0.0086 0.0043 0.300 0.746 
Vac?*VacAge 4 0.02831 0.02831 0.00708 0.490 0.744 
Error 29 0.4206 0.4206 0.0145   
Total 37 0.48875     
S = 0.120430   R-Sq = 13.94%   R-Sq(adj) = 0.00%   
 
 
 
 
Table VI: ANOVA results for IgG Concentrations Assayed Using ELISA for Samples 
Collected on Week 6 of Vaccine Trials 
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Analysis of Variance for KLH/BLK, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.244 0.0817 0.0408 0.170 0.842 
VacAge 2 1.2738 1.1409 0.5704 2.420 0.102 
Vac?*VacAge 4 0.3097 0.3097 0.0774 0.330 0.858 
Error 40 9.4481 9.4481 0.2362   
Total 48 11.2756     
S = 0.486008   R-Sq = 16.21%   R-Sq(adj) = 0.00%  
       
Analysis of Variance for KLH-Blank, using Adjusted SS for Tests 
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 0.002587 0.000997 0.000499 0.090 0.914 
VacAge 2 0.025339 0.026606 0.013303 2.410 0.103 
Vac?*VacAge 4 0.007414 0.007414 0.001854 0.340 0.852 
Error 40 0.220553 0.220553 0.005514   
Total 48 0.255894     
S = 0.0742552   R-Sq = 13.81%   R-Sq(adj) = 0.00%  
 
 
 
 
 
 
 
 
 
 
 
 
 
Production of Anti-KLH Ab 
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 Production of KLH-specific antibodies was measured. ANOVA was conducted to 
test the effect of vaccine treatment, age at vaccination, and the effect of vaccine treatment 
and age at vaccination.  
 Lambs vaccinated with KLH at age 0 weeks did produce anti-KLH Ab in 
response to the vaccine. At 2 and 4 weeks of age, the response was nearly 4 fold greater 
that levels produced by lambs that had received adjuvant only. By 6 weeks of age, the 
response was over 6 times higher in the KLH-vaccinated lambs compared to lambs that 
had received adjuvant alone (Fig. 5a). 
 Similarly, lambs vaccinated with KLH at age 5 weeks of age produced nearly 
seven times as much anti-KLH Ab in response to vaccine than lambs that had received  
adjuvant alone (Fig. 5b). The levels of anti-KLH IgG plateaued so that by week 6 anti-
KLH Ab  levels were still six to seven times the levels produced in lambs that had 
received adjuvant alone (Fig. 5a). This maximum level of anti-KLH antibody was also 
seen in the lambs vaccinated at 5 weeks of age, at the 7, 9, 11 week time points, (Fig. 
5b), and also in the lambs vaccinated at 10 months, at 42, and 44 weeks of age(Fig. 5c). 
Table VII shows that ANOVA shows that there were significant responses to KLH in 
related to  vaccination  in lambs vaccinated at all time points; 0, 5 weeks and 10 months 
of age (p≤0.001). When age at treatment was examined, there was a significant effect in 
lambs vaccinated at time 0 (p≤0.001), while the effect in the lambs vaccinated at 5 weeks 
of age was almost significant (p= 0.057). When these factors were crossed, there was a 
significant effect in lambs vaccinated at 5 weeks (p=0.040) an effect that approached 
significance for lambs vaccinated at 10 months of age (p=0.068).  
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 Figure 3 illustrates the anti-KLH Ab production as the levels of absorbance at 
405nm for the ELISA assay.  
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Anti-KLH Ab Production in Lambs Vaccinated at 0 Weeks 
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Anti-KLH Ab Production in Lambs Vaccinated at 5 Weeks
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C) 
 
Anti-KLH Ab Production in Lambs Vaccinated at 10 Months 
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Figure 5: Fold antibody production of anti-KLH Ab in lambs vaccinated with KLH at A) 
0 weeks of age, B) 5 weeks of age and, C) 10 months of age. Ab production was 
determined by ELISA as O.D 405nm; data was expressed as the fold response, anti-KLH 
IgG produced in the presence of KLH to that produced in control (media alone).  
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Table VII: ANOVA for anti-KLH AB Production in Sera 
Analysis of Variance for KLH, using Adjusted SS for 
Tests  
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 4.79095 4.83025 2.41512 36.86 0.000* 
VacAge 2 1.47694 1.47778 0.73889 11.28 0.000* 
Vac?*VacAge 4 0.54189 0.54189 0.13547 2.07 0.106* 
Error 35 2.29338 2.29338 0.06553   
Total 43 9.10316     
S = 0.255979   R-Sq = 74.81%   R-Sq(adj) = 69.05%  
Analysis of Variance for KLH, using Adjusted SS for 
Tests  
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 3.8925 3.8762 1.9381 15.860 0.000* 
VacAge 2 0.769 0.7584 0.3792 3.100 0.057* 
Vac?*VacAge 4 1.3706 1.3706 0.3427 2.800 0.040* 
Error 35 4.2761 4.2761 0.1222   
Total 43 10.3083     
S = 0.349536   R-Sq = 58.52%   R-Sq(adj) = 49.04%  
Analysis of Variance for KLH, using Adjusted SS for Tests  
Source DF SeqSS AdjSS AdjMS F P 
Vac? 2 6.7725 6.6936 3.3468 52.480 0.000* 
VacAge 1 0.0462 0.0378 0.0378 0.590 0.449 
Vac?*VacAge 2 0.3865 0.3865 0.1932 3.030 0.068* 
Error 23 1.4666 1.4666 0.0638   
Total 28 8.6717     
S = 0.252520   R-Sq = 83.09%   R-Sq(adj) = 79.41%  
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Discussion 
Conclusions 
 The primary objective of this project was to better understand the age at which 
immunological competency is achieved in postnatal Finnsheep x Dorset lambs. This was 
examined by creating a vaccine schedule to compare the immune responses of 0 week, 5 
week, and 10 month old lambs in response to KLH vaccines.  
 Vaccinating with KLH- Alum produced an immune response in all three age 
groups tested. According to the levels of lymphocyte proliferation and anti-KLH Ab in 
response to a KLH vaccine, lambs receiving vaccines as early as the first week of life can 
successfully launch an immune response, indicating that vaccines could be administered 
this early in sheep operations.  As mentioned by Chappuis, the antigenicity of vaccines 
administered early in the lamb’s life would have to be increased or paired with a foreign 
carrier molecule to promote an effective level of protective immunity in newborn lambs.   
 Additionally, similar to findings by J.M. Corpa, this study found that older lambs 
(7 weeks- 10 months of age) produced a stronger immune response in terms of higher 
levels of lymphocyte proliferation, IgG production, and KLH-specific Ab production. 
Therefore, it may be advantageous to wait approximately two months before 
administering vaccines that do not encourage as strong of an immune response to ensure 
that the vaccinations are successful.  
  Boosting also appears to be a viable method to improve the efficacy of vaccines 
administered to young lambs. The lymphocyte proliferation index in response to Con A 
and KLH exposure is greater than that of adjuvant alone by the second sample; four 
weeks after the first vaccine. This indicates that as Bar-Joseph et al. found, boosting helps 
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to increase the level of an immune response in lambs. The increased response to Con A 
indicates increased activation of unprimed T cells. The activated T cells will co-stimulate 
B cells and lead to a greater immune response. The proliferation index of PWM is greater 
than that of adjuvant alone starting on the first sample date. This indicates that there is 
already T cell dependent B cell activation occurring.  
 Given Fahey and Morris’ discovery that lambs can launch antigen-specific 
immune responses in utero, it was expected that the lambs would produce an antibody 
response to KLH vaccines. As the lambs and their dams were naïve to KLH exposure, no 
maternally-derived Ab interference was expected. This allowed examination of the 
lamb’s individual immune response and did not reflect the level of passive immunity 
present.  
 The anti-KLH Ab data indicates that lambs were producing KLH specific Ab after 
the first vaccine regardless of age. The response in the 2 week old lambs had half the 
amplitude of the response in the 6 week old lambs. Once lambs were six weeks or older, 
the immune response stayed relatively constant around a fold Ab production level of 1.8. 
This plateau indicates that once lambs reached 6 weeks they were producing the same 
strength immune response as the mature 10 month old lambs. This is a significant find as 
it helps determine when lambs exhibit a mature immune profile.  
 The total IgG data indicates that the adjuvant caused some IgG production. This is 
unusual as adjuvants are only supposed to serve as immuno-catalysts, increasing the 
antigenicity of a vaccine but having no response on its’ own. Whenever the adjuvant 
response was higher than the vaccine, the control response was as well. This indicates 
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that perhaps the total IgG production in lambs ages 7 and 9 weeks was low rather than the 
adjuvant response being high.  
 
Future Directions for this Research 
 To further understand the maturation of the lamb immune system, cytokine 
profiles should also be examined to further indicate when aspects of humoral and cell-
mediated immunity are activated by vaccination.  
 Finally, as this study examined the response to a completely foreign antigen, no 
maternal Ab blocking effect could be seen. Future research could focus on determining 
an immune system profile in lambs exposed to an antigen that the dam has been 
vaccinated against. This would indicate an appropriate timetable for administering the 
same vaccines that are given to the flock without losing the vaccine’s effectiveness to 
maternal Ab interference.  
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APPENDIX: 
A: Schedule of lamb vaccination and sampling dates. 
Age Group Vac 1 Smp1/ Vac2 Smp2/ Vac3 Smp 3 
Week 0A 30-Oct 13-Nov 27-Nov 11-Dec
Week 0B 9-Nov 22-Nov 8-Dec 20-Dec
Week 5A 5-Dec 19-Dec 2-Jan 16-Jan
Week 5B 14-Dec 29-Dec 11-Jan 25-Jan
Month 10 6-Nov 20-Nov 4-Dec 18-Dec
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